Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.13 EUR | -13.28% | -27.74% | -93.50% |
25/04 | Pharnext: share price rises on encouraging comments | CF |
06/03 | Pharnext: listing suspended pending further update | CF |
Business Summary
The group has a portfolio of 2 products in clinical development: PXT3003 (treatment of the orphan disease Charcot-Marie-Tooth type 1A) and PXT864 (Alzheimer's disease treatment).
Number of employees: 23
Sales per Business
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical Therapies
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -99.34% |
Sales per region
EUR in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
France
100.0
%
| 0 | 100.0 % | 0 | 100.0 % | -99.34% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Hugo Brugière
CEO | Chief Executive Officer | - | 08/22/08 |
Founder | - | 01/07/01 | |
Melissa Israel
CTO | Chief Tech/Sci/R&D Officer | - | 01/20/01 |
Philippe Rinaudo
CTO | Chief Tech/Sci/R&D Officer | - | 01/15/01 |
Xavier Paoli
COO | Chief Operating Officer | - | 01/14/01 |
Gilbert Wagener
CTO | Chief Tech/Sci/R&D Officer | - | 15/23/15 |
Joshua Schafer
BRD | Director/Board Member | 53 | 01/20/01 |
Antoine Gravelle
LAW | General Counsel | - | 01/22/01 |
Raj Thota
PRN | Corporate Officer/Principal | - | 19/21/19 |
Abhijit Pangu
LAW | General Counsel | - | 19/21/19 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
James Kuo
BRD | Director/Board Member | 58 | 16/22/16 |
Director/Board Member | 76 | 17/20/17 | |
Director/Board Member | 64 | 10/23/10 | |
Hugo Brugière
CEO | Chief Executive Officer | - | 08/22/08 |
Joshua Schafer
BRD | Director/Board Member | 53 | 01/20/01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 78 | 77 ( 99.00 %) | 0 | 99.00 % |
Company contact information
Sector
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-93.50% | 27.82K | |
+25.83% | 661B | |
+26.93% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+14.13% | 231B | |
+5.04% | 200B | |
-9.33% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- ALPHA Stock
- Company Pharnext SCA